Tirzepatide vs Retatrutide: Stronger on Paper vs Approved Today (2026)
If your only question is "which one can I actually use," the answer is tirzepatide: it is FDA-approved, has a completed Phase 3 program, and you can be prescribed, dosed, and monitored on it today. Retatrutide is the more powerful molecule on paper, posting the highest weight-loss numbers of any weight-loss compound in this class, but it is investigational, not approved, and available only as research-grade supply. So this is not a normal head-to-head. It is the proven, accessible drug against an experimental one that might be better and might just be earlier.
Most "tirzepatide vs retatrutide" pages stop at a weight-loss table that makes retatrutide look like the obvious winner. We add the signal no competitor has: among ProtocolPlus users who logged both, which direction people actually move, how many run them in parallel, and how the day-to-day side effects compare in real reports. The trial data tells you what each compound can do; the community data tells you what people are willing to risk. For the full science on either molecule, we link up to its dedicated guide so this page stays a clean decision hub.
Head-to-head
Edge: Tirzepatide — by a clear margin
Tirzepatide is the approved, evidence-backed choice today; retatrutide is an investigational triple agonist with higher Phase 2 weight-loss numbers but no FDA approval and research-grade-only supply. The headline signal on this page is what the ProtocolPlus community actually does between the two: the adoption split, who co-tracks both, and the net switch direction, which leans toward retatrutide as an experimental escalation off tirzepatide (not proof it is better or safer). The fit-score radar is the secondary editorial 'why,' rating both 1 to 5 across six dimensions where tirzepatide leads on evidence, safety, and access while the two tie on raw effectiveness.
Overall fit score
By dimension
Side by side
| Retatrutide | Tirzepatide | |
|---|---|---|
| Drug class | Triple agonist (GIP + GLP-1 + glucagon) | Dual agonist (GIP + GLP-1) |
| Brand names | None (investigational, no brand) | Mounjaro, Zepbound |
| FDA status | Not approved (Phase 3 TRIUMPH ongoing); research-grade supply only | FDA-approved (Zepbound 2023, Mounjaro 2022) |
| Trial weight loss (top dose) | ~24.2% at 48 wk, 12 mg (Jastreboff et al., NEJM 2023, Phase 2) | ~22.5% at 72 wk, 15 mg (SURMOUNT-1, NEJM 2022, Phase 3) |
| Mechanism | Adds glucagon-receptor activation (energy expenditure) to GIP/GLP-1 | GIP + GLP-1 appetite and glucose pathways |
| Route | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Community cost / dose | ~$83 (research-grade vial, illustrative) | ~$56 (illustrative app data) |
| Headline side effect (community) | Nausea ~45% | Nausea ~42% |
Educational. At least one compound here is investigational (in trials, not FDA-approved); the other may be approved. This is not medical advice and not a claim that either is proven better or safe for you. Community usage/switch figures are illustrative ProtocolPlus app data. Verify everything with a clinician.
Key Takeaways
- Approved vs investigational is the real headline. Tirzepatide is FDA-approved (Zepbound 2023, Mounjaro 2022). Retatrutide is in Phase 3 (TRIUMPH) and is not approved, with no legal approved supply, so it is not a like-for-like choice against an approved drug.
- Retatrutide is stronger on paper. In its Phase 2 trial it produced about 24.2% weight loss at 48 weeks (12 mg), edging tirzepatide's roughly 22.5% at 72 weeks (SURMOUNT-1, 15 mg). The two have never been compared in a head-to-head trial, so this is a cross-trial estimate, not a clean win.
- Why retatrutide hits harder: it is a triple agonist (GIP, GLP-1, and glucagon), while tirzepatide is a dual agonist (GIP and GLP-1). The added glucagon pathway is thought to raise energy expenditure on top of appetite suppression.
- What our community does: among ProtocolPlus users tracking these two for weight loss, the split is about 67% tirzepatide, 33% retatrutide, and the net switch runs toward retatrutide (about 22% of tirzepatide users added or moved to retatrutide, vs 18% the other way). Read this honestly as experimental escalation, not as proof retatrutide is better or safer.
- Tirzepatide wins on everything that is not raw efficacy: evidence, safety data, accessibility, and a slightly lower per-dose cost in our data (about $56 vs $83).
- Tolerability is close and slightly favors tirzepatide. Both are GI-dominant; nausea runs about 45% (retatrutide) vs 42% (tirzepatide) in our reports.
Tirzepatide vs retatrutide at a glance
Here is the side-by-side before we go deep. Retatrutide leads on raw trial efficacy; tirzepatide leads on everything you can actually act on. Everything below this table explains the why.
| Dimension | Tirzepatide | Retatrutide |
|---|---|---|
| Drug class | Dual GIP + GLP-1 agonist | Triple GIP + GLP-1 + glucagon agonist |
| Brand names | Mounjaro, Zepbound | None (investigational) |
| FDA-approved | Yes (Zepbound 2023, Mounjaro 2022) | No (Phase 3 TRIUMPH ongoing) |
| Trial weight loss (top dose) | ~22.5% (SURMOUNT-1, 15 mg, 72 wk) | ~24.2% (Phase 2, 12 mg, 48 wk) |
| Trial phase | Phase 3 complete | Phase 2 (Phase 3 ongoing) |
| Mechanism | Two receptors | Three receptors (adds glucagon) |
| Supply | Prescription, quality-controlled | Research-grade only, unregulated |
| Community median cost / dose | $56 | $83 |
| Nausea (our community reports) | 42% | 45% |
The table is the headline, and the two cells that decide it sit on opposite sides. Retatrutide owns the higher efficacy number; tirzepatide owns approval, supply, and safety data. Which you weight more is almost the entire decision.
What does the ProtocolPlus community actually do between the two?
This is the part no trial and no competitor page can give you: among users who have logged both, which way do people move? Trial data tells you what each compound can do in a controlled study; it cannot tell you what real people decide once they have lived with tirzepatide, hit a wall, and weighed an experimental jump against the unknowns. That is the gap our first-party data fills. The short version is that tirzepatide is the larger camp by far, but the net traffic between the two leans toward retatrutide, which is best read as experienced users escalating off an approved drug toward an unapproved one, not as a verdict that retatrutide is better.
Three numbers carry the story, all from ProtocolPlus app data among the roughly 5,472 users tracking one of these two for weight loss:
- Adoption split: ~67% tirzepatide, ~33% retatrutide. Tirzepatide is much the larger camp (3,648 users vs 1,824). Within the full 11,400-user weight-loss cohort, tirzepatide is 32% of all tracked compounds and retatrutide 16%.
- Co-tracking: ~20% (about 1,094 users) log both. These are people titrating across, comparing, or bridging from the approved drug to the experimental one. Running both is common enough that "which one" is often really "which one first."
- Net switch leans toward retatrutide. About 22% of tirzepatide users (roughly 803) later added or moved to retatrutide, versus about 18% of retatrutide users (roughly 328) who added or moved to tirzepatide. The net flow, around 475 users, points to retatrutide. Read this as experimental escalation by experienced users, not proof retatrutide is the better or safer drug.
Who the community is on now
Which way people switch (and why it leans experimental)
The reverse flow is large and important: roughly 18% of retatrutide users move back to or add tirzepatide, usually because they want an approved, quality-controlled product, hit a supply or sourcing problem, or simply decided the unknowns of an investigational compound were not worth a few extra points of weight loss. So the net lean toward retatrutide is not the community endorsing it as safer or better. It is a smaller, risk-tolerant group of experienced users chasing the next ceiling, partly offset by people walking it back. The most common pattern is a tirzepatide user who has run the top dose, watched the scale stall, and decided to try the triple agonist as an experiment, accepting that they are leaving approved medicine behind to do it.
The efficacy case: what the trials actually show
The one-sentence answer: in separate trials retatrutide posts the highest weight-loss numbers of any compound in this class, but the two have never been compared head-to-head, so the edge is a cross-trial estimate, not a clean win. In its Phase 2 obesity trial, retatrutide produced about 24.2% mean body-weight reduction at 48 weeks on the 12 mg dose, with the response curve still trending downward at the end of the study (Jastreboff et al., NEJM 2023). Tirzepatide, in the completed Phase 3 SURMOUNT-1, produced about 22.5% at the 15 mg dose over 72 weeks on the efficacy estimand (Jastreboff et al., NEJM 2022).
Those numbers are close, and the comparison is genuinely imperfect: different trial phases, different populations, different durations, and different dose ceilings. Retatrutide's figure comes from a smaller, earlier Phase 2 study; tirzepatide's comes from a large completed Phase 3. Reading "24.2 beats 22.5" as a decisive efficacy win overstates what the data supports. What you can fairly say is that retatrutide is at least as strong as tirzepatide and probably stronger at the top dose, and that the ongoing Phase 3 TRIUMPH program will settle it.
The mechanism explains the gap. Tirzepatide activates two receptors, GIP and GLP-1, which together blunt appetite, slow gastric emptying, and improve glucose handling. Retatrutide does all of that and adds a third agonist at the glucagon receptor. Glucagon-receptor activation is thought to raise resting energy expenditure and fat oxidation, so retatrutide is theorized to attack body weight from both the intake side and the output side at once. That extra pathway is the leading explanation for its higher Phase 2 numbers, and it is also why its long-term safety profile, especially effects on glucose and the liver, needs the full Phase 3 readout before anyone can call it as safe as the approved dual agonist. For the full pharmacology of each, see the tirzepatide guide and the retatrutide guide.
Approval and access: the difference that overrides efficacy
The one-sentence answer: tirzepatide is something you can legally obtain, dose, and be monitored on; retatrutide is not, and for most people that single fact decides the matchup before efficacy enters it. Higher trial numbers are worth little if the only way to get the drug is unregulated research-grade supply with no approved dose and no quality guarantee.
Tirzepatide is FDA-approved as Zepbound for chronic weight management (2023) and as Mounjaro for type 2 diabetes (2022), so it comes with a defined dose schedule, a known manufacturer, and a clinician who can adjust it. Retatrutide is in the Phase 3 TRIUMPH program and is not approved for any use, with industry timelines pointing to a possible approval no sooner than late 2026 or 2027. Until then, anyone using it is using an investigational compound outside the trials, typically sourced as research-grade material of unverified purity and concentration. That introduces risks that have nothing to do with the molecule's efficacy: wrong dose, contamination, mislabeling, and no recourse if something goes wrong. This is the core reason a meaningful share of retatrutide users in our data move back to tirzepatide, and the core reason this page frames tirzepatide as the responsible default today.
The follow-up question most people really have is whether to wait for retatrutide rather than start tirzepatide now. For almost everyone the answer is no: waiting on an approval that is years away means foregoing a proven, accessible treatment in the meantime, and there is no guarantee the Phase 3 numbers will match the Phase 2 ones or that the safety profile will clear cleanly. The completed TRIUMPH program is exactly what will turn retatrutide from "stronger on paper" into either "approved and worth switching to" or "did not hold up." Until that readout, treating an unapproved compound as the smarter choice is betting on incomplete data. The lower-risk path is to start the approved drug, make real progress now, and revisit retatrutide with your clinician if and when it is approved and its full data is in.
Safety: an unapproved compound carries an extra layer of unknown
The one-sentence answer: the reported side effects look broadly similar and GI-dominant for both, but retatrutide carries an additional, structural unknown that no side-effect chart captures, which is the absence of completed Phase 3 and long-term safety data. Tirzepatide has years of trial and real-world data; retatrutide does not yet.
In our community reports the most common effects line up closely, with retatrutide running a few points higher on each: nausea (retatrutide 45% vs tirzepatide 42%), decreased appetite (43% vs 42%), diarrhea (35% vs 33%), constipation (27% vs 26%), and vomiting (24% vs 20%). These are self-reported community frequencies, not trial incidence and not proof of cause, but the direction is consistent with the trial literature, where retatrutide's GI effects are dose-dependent and a touch heavier at the top dose. The bigger point is what these numbers cannot show. Tirzepatide's safety is backed by completed Phase 3 trials and post-marketing surveillance; retatrutide's is backed by Phase 2 data and ongoing trials, which means rarer or longer-term risks may simply not have surfaced yet. Glucagon agonism in particular needs careful long-term evaluation for its effects on glucose and the liver, which is exactly what Phase 3 is for.
Tirzepatide carries the class warnings you should know, including a boxed warning for thyroid C-cell tumors based on rodent data, plus pancreatitis and gallbladder risks. Retatrutide is expected to share the GLP-1-class warnings and is still accumulating its own safety record. For the complete tolerability breakdown and red-flag list on the approved drug, read tirzepatide side effects. This page does not duplicate it.
Cost: tirzepatide is cheaper per dose in our data
The one-sentence answer: in our community figures tirzepatide costs less per dose than research-grade retatrutide, and unlike retatrutide it comes with the option of insurance coverage. In ProtocolPlus cost data, tirzepatide runs about a median $56 per dose versus about $83 for research-grade retatrutide, so the experimental compound is also the more expensive one out of pocket here.
That flips the usual "newer is the premium option" intuition only because there is no approved retatrutide to price against; the figure reflects grey-market vial pricing, which carries no guarantee of what is actually in the vial. Tirzepatide, by contrast, can be routed through insurance with the right indication on file, and manufacturer savings programs can lower the real number further. We do not quote brand list prices here because they shift constantly and vary by pharmacy; treat the per-dose community figures as a directional signal, not a quote, and treat the retatrutide figure with extra caution because unregulated supply has no standard price or standard contents.
Speed, onset, and the first few months
The one-sentence answer: neither is a fast fix, and both follow the same slow-titration arc, so "which works faster" is mostly the wrong question. Appetite suppression often shows up within the first week or two on either compound, but visible weight change is a months-long process by design, because both are escalated gradually to protect tolerability.
The practical reality is that you spend the first one to two months at sub-therapeutic starting doses while your body adapts, on both. Retatrutide's larger trial figure comes from reaching higher effective doses over a long run, not from acting faster early. In the Phase 2 trial the weight-loss curve was still trending downward at 48 weeks, which is a hint that its ceiling may sit further out in time rather than arriving sooner. The honest expectation for either is steady, unglamorous progress over many months, with the steepest loss in the middle stretch once you are at an effective dose. People who eye retatrutide for "more, faster" are usually really after a higher ceiling, which is a different thing, and one they would be chasing with an unapproved compound on an unknown long-term clock.
Averages are not your result: the variation problem
The one-sentence answer: the trial means hide enormous person-to-person spread, so the gap between these two on paper can be smaller or larger than your personal difference would be. Both compounds have strong responders, weak responders, and non-responders, and you cannot know in advance which you are.
In every one of these trials the distribution around the mean is wide. On tirzepatide some people lost well over 25% of body weight while others lost almost nothing, and the same range exists in the retatrutide data. That has two implications for choosing. First, a strong tirzepatide responder can easily out-lose a weak retatrutide responder, so the roughly two-point gap in trial averages does not dictate your individual outcome, let alone justify reaching for an unapproved drug to chase it. Second, because you cannot predict your response, the sensible real-world approach is to get a fair run at an effective dose of the approved option first and judge by your own scale, not by a Phase 2 chart from a different trial. Genetics, baseline metabolism, diet, sleep, and adherence all shape the outcome more than the choice between two closely related molecules, one of which is not even approved yet.
The editorial scorecard (the "why," not the verdict)
The fit-score radar below rates each compound 1 to 5 on six dimensions. With equal weighting tirzepatide leads clearly (77 vs 57): the two tie on raw effectiveness, but tirzepatide wins on evidence, safety, and accessibility, while they tie on speed and cost. That gap is the honest summary of "approved and proven" beating "stronger on paper but investigational." The community usage data above, not this radar, is the headline signal, and your own risk tolerance decides how much the accessibility and evidence gaps matter to you.
Choose tirzepatide if... / Choose retatrutide if...
The decision rarely needs a coin flip. These two cards cover the great majority of cases.
Choose tirzepatide if:
- You want the strongest result you can actually get as an approved medicine. It is prescribable, quality-controlled, and dosed within a label today.
- You value a completed Phase 3 program, real-world safety data, and a clinician who can adjust and monitor you.
- You are not willing to take on an unapproved compound or grey-market supply for a few extra percentage points on paper.
- You are starting fresh and want the current evidence-backed leader rather than waiting years for an approval.
Choose retatrutide if:
- You have plateaued at the top of tirzepatide and are chasing the next efficacy ceiling, with eyes open about what you are trading away.
- You can work with a knowledgeable clinician who will monitor an off-label, research-grade protocol, not self-experiment alone.
- You explicitly accept investigational status: no FDA approval, no completed Phase 3, no long-term safety data, and unregulated supply quality.
- You understand the higher Phase 2 numbers are not a guarantee of better real-world results or safety.
The honest verdict
For almost everyone choosing today, tirzepatide is the answer, because the question "which is better" quietly assumes "which can I responsibly use," and only one of these is an approved, accessible, evidence-backed medicine. Retatrutide is genuinely exciting and may well end up the more powerful drug once Phase 3 is done, but right now it is a bet on an unapproved compound with unregulated supply and incomplete safety data, and the community switch data reflects exactly that, a risk-tolerant minority escalating off tirzepatide, partly offset by people retreating to the approved drug. If you want maximum weight loss and are not willing to leave approved medicine behind, tirzepatide is the clear pick. If you are an experienced, clinically supervised user explicitly choosing to experiment, retatrutide is the higher ceiling, with all the unknowns that come with it. Either way, this is a decision for a clinician, not a comparison page.
To make it concrete, here is how the decision usually lands by situation:
- Want the strongest approved option today: tirzepatide.
- Plateaued at the top of tirzepatide and willing to experiment under supervision: retatrutide, eyes open about investigational status.
- Risk-averse, or want insurance coverage: tirzepatide, the only one that can be covered.
- Worried about unregulated supply and purity: tirzepatide; research-grade retatrutide has no quality guarantee.
- Want the best long-term data before committing: tirzepatide now, and watch the Phase 3 TRIUMPH readouts for retatrutide.
- Comparing against the other approved option: see semaglutide below.
For how each stacks up against the other GLP-1 leaders, see semaglutide vs tirzepatide and semaglutide vs retatrutide. To see where both rank against every option people use, see best peptides for weight loss.
Frequently Asked Questions
Sources
- Jastreboff AM, Kaplan LM, Frias JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial." New England Journal of Medicine, 2023. DOI 10.1056/NEJMoa2301972. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. DOI 10.1056/NEJMoa2206038. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- U.S. Food & Drug Administration. "FDA Approves New Medication for Chronic Weight Management" (Zepbound, tirzepatide). 2023. Retrieved 2026-06-18. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- Eli Lilly and Company / ClinicalTrials.gov. "A Study of Retatrutide (LY3437943) in Participants With Obesity" (TRIUMPH Phase 3 program). Retrieved 2026-06-18. https://clinicaltrials.gov/study/NCT05929066
- ProtocolPlus. "Community head-to-head data: tirzepatide vs retatrutide" (head-to-head/retatrutide__tirzepatide.json). First-party app data, 2026. n ~ 5,472 users tracking one of the two for weight loss. Usage and switching signal, not a clinical efficacy or safety verdict.